Universal Health International Group Holding Ltd. (2211) AI Stock Analysis

• Market Cap: HK$99.33M
• Dividend Yield: N/A
• Average Volume (3M): 445.71K
• Price to Earnings (P/E): 5.2
• Beta (1Y): 1.11
• Revenue Growth: -15.49%
• EPS Growth: N/A
• Country: HK
• Employees: 1,198
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.11
• Shares Outstanding: 80,105,960
• 10 Day Avg. Volume: 788,978
• 30 Day Avg. Volume: 445,713
• PEG Ratio: 0.02
• Price to Book (P/B): 2.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$1.00
• Price Target Upside: -19.35% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 59 Neutral
• Price Target: HK$1.50 ▲(20.97%Upside)

The stock's overall score is primarily influenced by its financial performance, which highlights significant challenges such as declining revenues and profitability. Technical analysis provides a positive outlook with strong momentum, offsetting some of the financial concerns. Valuation suggests the stock may be undervalued, but the lack of a dividend yield reduces its appeal. Earnings call and corporate events do not contribute to the score due to lack of data.

Universal Health International Group Holding Ltd. Business Overview & Revenue Model

Company Description

Universal Health International Group Holding Ltd. (2211) is a company primarily engaged in the distribution and retail of pharmaceutical and healthcare products. It operates through various segments, including the wholesale and retail of medicines, healthcare products, and medical devices, primarily within the Chinese market. The company leverages its extensive distribution network to serve a wide range of customers, ranging from hospitals and clinics to individual consumers.

How the Company Makes Money

Universal Health International Group Holding Ltd. generates revenue through the sale of pharmaceutical and healthcare products. Its primary revenue streams include the wholesale distribution of medicines to healthcare institutions, retail sales through pharmacies and online platforms, and the provision of medical devices. The company benefits from strategic partnerships with pharmaceutical manufacturers, enabling it to offer a diverse range of products. Additionally, its expansive distribution network and focus on the growing Chinese healthcare market contribute significantly to its earnings.

Universal Health International Group Holding Ltd. Financial Statement Overview

Summary

Universal Health International Group Holding Ltd. is experiencing financial struggles with declining revenues and minimal profitability. Although a positive net income was achieved in 2024, operational efficiencies are lacking, and cash flow issues persist. The balance sheet shows moderate leverage but limited profitability from equity.

Income Statement

The company has experienced declining revenue over the past few years, with a significant drop from 2019 to 2024. In 2024, the gross profit margin is approximately 16.52%, which is low, indicating cost management issues. Despite a positive net income for the first time in years, the net profit margin remains minimal at 0.38%. The EBIT and EBITDA margins are also very slim, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a relatively stable equity position, with a modest debt-to-equity ratio of 0.20 in 2024, suggesting reasonable leverage. However, the equity ratio has decreased over the years, standing at 50.90% in 2024. The return on equity in 2024 is low at 0.12%, indicating limited profitability from shareholders' equity.

Cash Flow

Cash flow analysis reveals significant challenges, with negative operating cash flow and free cash flow in 2024. The company has not shown substantial improvement in cash flow generation over the years. The operating cash flow to net income ratio is negative, reflecting poor cash conversion from profits.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	1.09B	1.46B	1.54B	1.39B	1.67B
Gross Profit	179.88M	222.60M	215.32M	56.19M	160.56M
EBITDA	12.59M	-82.27M	-160.78M	-560.83M	-446.66M
Net Income	413.00K	-118.73M	-226.85M	-790.91M	-544.69M
Balance Sheet
Total Assets	692.88M	797.10M	983.55M	1.15B	1.64B
Cash, Cash Equivalents and Short-Term Investments	36.92M	89.37M	103.48M	81.51M	193.43M
Total Debt	70.60M	93.18M	81.56M	46.46M	65.05M
Total Liabilities	339.99M	457.57M	504.47M	459.02M	273.63M
Stockholders Equity	352.72M	339.53M	478.40M	691.04M	1.36B
Cash Flow
Free Cash Flow	-101.75M	-19.47M	-47.94M	-126.92M	-555.63M
Operating Cash Flow	-101.73M	-19.40M	-47.81M	-124.67M	-449.52M
Investing Cash Flow	54.88M	460.72K	4.81M	9.33M	-109.65M
Financing Cash Flow	40.23M	12.70M	67.66M	-11.96M	7.85M

Universal Health International Group Holding Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2211, the sentiment is Positive. The current price of 1.24 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.12, and below the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 54.95 is Neutral, neither overbought nor oversold. The STOCH value of 31.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2211.

Universal Health International Group Holding Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$388.46M	9.03	5.95%	9.69%	0.81%	27.55%
1110	71 Outperform	HK$345.70M	7.29	6.61%	9.76%	-3.59%	4.81%
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.90%	11.55%	-28.15%
2211	59 Neutral	HK$99.33M	5.21	4.03%	―	-15.49%	―
2393	54 Neutral	HK$370.41M	0.37	1417.08%	―	-20.01%	―
3390	45 Neutral	HK$326.31M	86.90	0.64%	19.18%	-26.91%	-98.72%
2197	45 Neutral	HK$661.50M	―		―	-1.73%	-689.53%

Universal Health International Group Holding Ltd. Corporate Events

Universal Health International Approves Key Subscription Agreement

Universal Health International Group Holding Ltd. announced the successful passage of a resolution at its extraordinary general meeting held on July 23, 2025. The resolution, which was approved unanimously, involves a subscription agreement with Huang Yu Holdings Limited, allowing the company to issue new shares. This move is expected to enhance the company’s financial flexibility and support its growth strategy, potentially impacting its market positioning positively.

Universal Health International Announces EGM for Strategic Share Issuance

Universal Health International Group Holding Limited has announced an extraordinary general meeting (EGM) to be held on July 23, 2025, in Shenyang City, China. The meeting will address a subscription agreement with Huang Yu Holdings Limited, involving the issuance of over 30 million shares at HK$0.80 each. This strategic move is expected to impact the company’s capital structure and potentially enhance its market positioning.

Universal Health International Delays Circular Dispatch for Share Subscription

Universal Health International Group Holding Limited, a company incorporated in the Cayman Islands, has announced a delay in the dispatch of a circular related to the subscription of new shares under a specific mandate. The circular, which was initially expected to be sent to shareholders by June 30, 2025, will now be dispatched on or before July 4, 2025, due to the need for additional time to prepare and finalize certain information.

Universal Health International Delays Circular Dispatch for Share Subscription

Universal Health International Group Holding Ltd., incorporated in the Cayman Islands, has announced a delay in the dispatch of a circular related to the subscription of new shares under a specific mandate. The circular, initially expected to be sent to shareholders by June 17, 2025, will now be dispatched by June 30, 2025, due to the need for additional time to prepare and finalize certain information.

Universal Health International Announces Delay in Circular Dispatch

Universal Health International Group Holding Ltd. announced a delay in the dispatch of a circular related to the subscription of new shares. The circular, originally expected by June 3, 2025, will now be dispatched by June 17, 2025, due to the need for additional time to prepare and finalize certain information. This delay may impact shareholder expectations and the company’s timeline for executing its strategic initiatives.

Universal Health International Approves Share Consolidation

Universal Health International Group Holding Ltd. announced the results of its Extraordinary General Meeting held on May 28, 2025, where a resolution for share consolidation was approved unanimously. The share consolidation will be effective on May 30, 2025, impacting the trading of shares and the adjustment of share options, which could influence the company’s stock market performance and shareholder value.

Universal Health Clarifies Ownership Structure in Share Subscription

Universal Health International Group Holding Ltd. issued a clarification regarding the ownership structure of a subscriber involved in a share subscription under a specific mandate. The company corrected a clerical error, confirming that the subscriber is wholly owned by Ms. Guo Bing, with a subsidiary owned 89% by the subscriber and 11% by the company. This announcement maintains the integrity of the company’s disclosure practices, ensuring accurate information for stakeholders.

Universal Health International Announces New Share Subscription to Boost Capital

Universal Health International Group Holding Ltd. has entered into a Subscription Agreement to issue new shares, raising approximately HK$24.35 million. This move, which involves a significant portion of the company’s share capital, is intended to bolster the company’s general working capital and enhance its financial stability. The subscription is contingent upon several conditions, including shareholder approval and share consolidation, highlighting the company’s strategic efforts to strengthen its market position.

Universal Health International Proposes Share Consolidation at Upcoming EGM

Universal Health International Group Holding Ltd. has announced an extraordinary general meeting (EGM) to discuss a proposed share consolidation. The proposal involves consolidating every ten issued and unissued ordinary shares into one, subject to approval by the Stock Exchange of Hong Kong Limited. This move is aimed at streamlining the company’s share structure and potentially enhancing share value, which could have implications for shareholders and market positioning.

Universal Health International Proposes Share Consolidation

Universal Health International Group Holding Ltd. has announced a proposed share consolidation, where every ten issued and unissued existing shares of US$0.01 will be consolidated into one consolidated share of US$0.10. This move is subject to shareholder approval at an Extraordinary General Meeting (EGM) and compliance with relevant legal and listing requirements. The consolidation aims to streamline the company’s share structure, although it may result in the creation of odd lots, which could affect trading dynamics. Shareholders and investors are advised to exercise caution and consult professional advisers.